<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621786</url>
  </required_header>
  <id_info>
    <org_study_id>MH125126</org_study_id>
    <secondary_id>MH125126</secondary_id>
    <nct_id>NCT04621786</nct_id>
  </id_info>
  <brief_title>Electroconvulsive Therapy Amplitude Titration</brief_title>
  <official_title>Electroconvulsive Therapy Amplitude Titration for Improved Clinical Outcomes in Late Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Zucker Hillside Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Mind Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is focused on advancing ECT treatment for older adults with depressive disorders&#xD;
      by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amplitude titration, as proposed in this current proposal, can reduce the variability related&#xD;
      to fixed amplitude dosing and optimize clinical and cognitive outcomes. The goal of this&#xD;
      project is to change standard ECT parameter selection from a fixed amplitude to an&#xD;
      individualized and empirically determined amplitude. To achieve this goal, the investigators&#xD;
      will focus on the relationship between amplitude titration and treatment-responsive changes&#xD;
      in hippocampal neuroplasticity with RUL fixed amplitude ECT. Fixed amplitude ECT results in&#xD;
      variable E-field or ECT dose. Over the course of an ECT series, the variable ECT dose will&#xD;
      result in inconsistent changes in hippocampal neuroplasticity. In contrast, pre-translational&#xD;
      investigations have demonstrated that amplitude titration results in a consistent E-field or&#xD;
      ECT &quot;dose&quot;. Seizure titration amplitudes (based on historic data, 233 to544mA) are below the&#xD;
      amplitude range of FDA-approved ECT devices (500 to 900mA) and will require an adaptor to&#xD;
      reduce the output amplitude (Investigational Device Exemption). Amplitude titration will also&#xD;
      be below the hippocampal neuroplasticity threshold and insufficient for antidepressant&#xD;
      response. The difference between RUL amplitude titration and RUL fixed amplitude (800mA) ECT&#xD;
      will determine the degree of target engagement with the hippocampus. To illustrate, subjects&#xD;
      with low amplitude titration of ~250 mA (800/250, high fixed/titration amplitude ratio) will&#xD;
      have significant changes in hippocampal neuroplasticity. Subjects with high amplitude&#xD;
      titration ~500mA (800/500, low fixed/titration ratio) will have minimal changes in&#xD;
      hippocampal neuroplasticity. The relationship between amplitude titration and fixed amplitude&#xD;
      hippocampal neuroplasticity will be used to develop the amplitude multiplier required for&#xD;
      consistent and clinically effective ECT dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inventory of Depressive Symptomatology - Clinician (IDS-C)</measure>
    <time_frame>The time frame is four weeks (before and after the ECT series).</time_frame>
    <description>The IDS-C is a clinician rating of depression severity. The scoring range is from 0 to 84 with higher scores related to higher depression severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delis-Kaplan Executive Function System verbal fluency (DKEFS) test score</measure>
    <time_frame>The time frame is four weeks (before and after the ECT series).</time_frame>
    <description>The DKEFS-VF is a neuropsychological measure of executive functioning. The scoring range (scaled scores) is between 1 to 19 with higher scores related to superior executive functioning.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface</intervention_name>
    <description>The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of major depressive disorder&#xD;
&#xD;
          -  Clinical indications for ECT with right unilateral electrode placement&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Age range between 50 and 80 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury,&#xD;
             epilepsy, Alzheimer's disease)&#xD;
&#xD;
          -  Other psychiatric conditions (e.g., schizophrenia, bipolar disorder)&#xD;
&#xD;
          -  Current drug or alcohol use disorder (except for nicotine); and 4) contraindications&#xD;
             to MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Abbott, MD</last_name>
    <phone>5052723507</phone>
    <email>cabbott@salud.unm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>megan lloyd</last_name>
    <phone>5052723507</phone>
    <email>meglloyd@salud.unm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Abbott, MD</last_name>
      <phone>505-272-2223</phone>
      <email>cabbott@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Lloyd, MS</last_name>
      <phone>5052723507</phone>
      <email>meglloyd@salud.unm.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroconvulsive Therapy</keyword>
  <keyword>Depressive Episode</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

